Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
TFF Pharmaceuticals, Inc is a biotechnology business based in the US. TFF Pharmaceuticals shares (TFFP) are listed on the NASDAQ and all prices are listed in US Dollars. TFF Pharmaceuticals employs 4 staff and has a market cap (total outstanding shares value) of USD$351.2 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$3.44 - USD$21.14 |
---|---|
50-day moving average | USD$17.3188 |
200-day moving average | USD$15.5455 |
Wall St. target price | USD$27 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.997 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -40.34% |
Return on equity TTM | -68.75% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$351.2 million |
TTM: trailing 12 months
There are currently 306,962 TFF Pharmaceuticals shares held short by investors – that's known as TFF Pharmaceuticals's "short interest". This figure is 59.7% down from 761,226 last month.
There are a few different ways that this level of interest in shorting TFF Pharmaceuticals shares can be evaluated.
TFF Pharmaceuticals's "short interest ratio" (SIR) is the quantity of TFF Pharmaceuticals shares currently shorted divided by the average quantity of TFF Pharmaceuticals shares traded daily (recently around 383702.5). TFF Pharmaceuticals's SIR currently stands at 0.8. In other words for every 100,000 TFF Pharmaceuticals shares traded daily on the market, roughly 800 shares are currently held short.
However TFF Pharmaceuticals's short interest can also be evaluated against the total number of TFF Pharmaceuticals shares, or, against the total number of tradable TFF Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TFF Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 TFF Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0184% of the tradable shares (for every 100,000 tradable TFF Pharmaceuticals shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TFF Pharmaceuticals.
Find out more about how you can short TFF Pharmaceuticals stock.
We're not expecting TFF Pharmaceuticals to pay a dividend over the next 12 months.
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza vaccines; and cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases for use of its thin film freezing technology platform. TFF Pharmaceuticals, Inc. also has a joint development and collaboration agreement with Augmenta Bioworks, Inc. to develop commercial products incorporating Augmenta's human-derived monoclonal antibodies for COVID-19 therapeutics. The company was founded in 2018 and is based in Austin, Texas.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.